SPECIAL NOTICE
66 -- Induced pluripotent stem (iPS) cell-derived differentiated cells
- Notice Date
- 7/24/2020 8:10:44 AM
- Notice Type
- Special Notice
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NCATS-20-003434
- Response Due
- 7/31/2020 11:00:00 AM
- Archive Date
- 08/01/2020
- Point of Contact
- Robin Knightly, Phone: 13018275302, Valerie Whipple, Phone: 3018275218
- E-Mail Address
-
Robin.knightly@nih.gov, Valerie.whipple@nih.gov
(Robin.knightly@nih.gov, Valerie.whipple@nih.gov)
- Description
- PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE Solicitation: NIMH-20-003434 Title: Induced pluripotent stem (iPS) cell-derived differentiated cells INTRODUCTION PURSUANT TO FAR Subpart 5.2�Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION. �� THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).� The National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH) intends to intends to solicit by a request for quotation from Fujifilm Cellular Dynamics International, Inc. for award on or around August 15, 2020.� The purpose of this purchase order will be to provide the National Center for Advancing Translational Sciences (NCATS) with Induced pluripotent stem (iPS) cell-derived differentiated cells. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541714 � Research and Development in Biotechnology (except Nanobiotechnology) with a size standard of 1,000 employees. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses of the Federal acquisition Requlation (FAR) in effect through the Federal Acquisition Circular 2020-04 dated January 15, 2020. STATUTORY AUTHORITY This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures and FAR Part 12�Acquisition of Commercial Items and is expected to exceed the simplified acquisition threshold. FAR Subpart 13.106-1 (b) Soliciting from a single Source provides that: For purchases not exceeding the simplified acquisition threshold, Contracting officers may solicit from one source IF the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name OR industrial mobilization). DESCRIPTION OF REQUIREMENT Purpose and Objectives The purpose of this acquisition is to procure Induced pluripotent stem (iPS) cell-derived differentiated cells for the National Center for Advancing Translational Sciences (NCATS).� The Tissue BioPrinting Lab at NCATS is using these iPS cells to bioprint 3D tissue models of the brain to study the effects of new therapies for pain, opioid addiction and overdose. With these cells we are developing human 3D tissue models, and the only source of large amounts of human dopaminergic, gabanergic and glutaminergic is through differentiation of iPSC cells. Delivery or Deliverables Please see the attached Purchase Description for further details. CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.www.sam.gov.� All responses must be received by July 31, 2020 at 2:00 p.m., Eastern Standard Time, and reference number NIMH-20-003434. Responses may be submitted electronically to Robin Knightly, Contract Specialist, at Robin.Knightly@nih.gov. Fax responses will not be accepted. Extensions to the deadline will not be granted. Please contact Robin Knightly, Contract Specialist, at Robin.Knightly@nih.gov or (301) 827-5302 with any questions.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/71922c2fc04648edb6862b619a7782be/view)
- Place of Performance
- Address: Bethesda, MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN05732709-F 20200726/200724230143 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |